Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from Ongoing Phase 2 Study to be Presented at 1:15 PM CT at the 2018 American Society of Clinical...




